These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3323467)

  • 21. Peripheral vasodilators versus pentoxifylline for the treatment of intermittent claudication.
    Aviado DM
    Ric Clin Lab; 1983; 13 Suppl 3():263-8. PubMed ID: 6143383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of response to pentoxifylline therapy in patients with intermittent claudication.
    Thomas JH; Swannack CJ; McAnaw M; Klein S; Kinnaman ML; Iliopoulos JI; Hermreck AS; Pierce GE
    Am J Surg; 1987 Dec; 154(6):663-5. PubMed ID: 3425814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of claudication with pentoxifylline: are benefits related to improvement in viscosity?
    Johnson WC; Sentissi JM; Baldwin D; Hamilton J; Dion J
    J Vasc Surg; 1987 Sep; 6(3):211-6. PubMed ID: 3625877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pentoxifylline in the treatment of intermittent claudication of the lower limbs.
    Reich T; Cutler BC; Lee BY; Porter JM; Reichle FA; Scogin JT; Strandness DE
    Angiology; 1984 Jul; 35(7):389-95. PubMed ID: 6380347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug treatment of claudication: vasodilators, hemorrheologic agents, and antiserotonin drugs.
    Taylor LM; Porter JM
    J Vasc Surg; 1986 Feb; 3(2):374-81. PubMed ID: 2935646
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapeutic results with xanthine derivatives in the intermittent claudication syndrome in diabetic patients].
    Gómez Reyes D; Rojas Hidalgo E
    Rev Clin Esp; 1988 Jan; 182(1):3-6. PubMed ID: 3375512
    [No Abstract]   [Full Text] [Related]  

  • 27. [Use of pentoxifylline in diabetes with intermittent claudication].
    Petruzzi E; Bucalossi A; Corri S; Marsilii A; Di Noto C
    Ric Clin Lab; 1983; 13 Suppl 3():451-4. PubMed ID: 6673028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pentoxifylline: a new agent for intermittent claudication.
    Baker DE; Campbell RK
    Drug Intell Clin Pharm; 1985 May; 19(5):345-8. PubMed ID: 3891279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The influence of chronic pentroxifylline medication on ergometric and hemodynamic parameters in intermittent claudication (author's transl)].
    Rudofsky G; Brock FE; Ulrich M; Nobbe F
    Med Klin; 1979 Jul; 74(28-29):1093-6. PubMed ID: 556192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects.
    Reilly DT; Quinton DN; Barrie WW
    N Z Med J; 1987 Jul; 100(828):445-7. PubMed ID: 3330188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemorheology and therapy of vascular disease.
    Savitsky JP
    Am Pharm; 1986 Aug; NS26(8):38-40. PubMed ID: 3776830
    [No Abstract]   [Full Text] [Related]  

  • 32. Another look at the pentoxifylline efficacy data for intermittent claudication.
    Gillings D; Koch G; Reich T; Stager WJ
    J Clin Pharmacol; 1987 Aug; 27(8):601-9. PubMed ID: 3655008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of arterial diseases with trental 400. Results of a double-blind study].
    Völker D
    Med Welt; 1978 Aug; 29(32):1244-7. PubMed ID: 672594
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.
    Aviado DM; Dettelbach HR
    Angiology; 1984 Jul; 35(7):407-17. PubMed ID: 6380349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Training by walking and drug therapy of peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Gerhards M; Leipnitz G
    Vasa Suppl; 1987; 20():384-7. PubMed ID: 3321495
    [No Abstract]   [Full Text] [Related]  

  • 36. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects.
    Aviado DM; Porter JM
    Pharmacotherapy; 1984; 4(6):297-307. PubMed ID: 6393073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group.
    Dettori AG; Pini M; Moratti A; Paolicelli M; Basevi P; Quintavalla R; Manotti C; Di Lecce C
    Angiology; 1989 Apr; 40(4 Pt 1):237-48. PubMed ID: 2650578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of pentoxifylline for end-stage peripheral vascular disease.
    Loyd RG; Prian GW; Gomez H; Laub J; Mertz GH
    Angiology; 1987 Apr; 38(4):304-8. PubMed ID: 3578918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Photoplethysmographic documentation of improved microcirculation after pentoxifylline therapy.
    Roeren T; LeVeen RF; Nugent L
    Angiology; 1988 Nov; 39(11):929-33. PubMed ID: 3177959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication.
    Rao KM; Simel DL; Cohen HJ; Crawford J; Currie MS
    J Lab Clin Med; 1990 Jun; 115(6):738-44. PubMed ID: 2366034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.